SLC5A2 and Hypoglycemia: A potential clinical question linked to SGLT2 inhibitor therapy as adjunctive-to-insulin in T1DM is the degree of possible insulin dose adjustment that may be required upon initiation of treatment to minimize a potential hypoglycemia risk.